Le Lézard
Classified in: Health, Science and technology
Subject: Stock Sale/Buyback

InVivo Therapeutics Announces Closing of Public Offering of Common Stock


InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) today announced the closing of its previously announced public offering of 7,000,000 shares of its common stock, par value $0.00001 per share, at a price to the public of $0.12 per share. The gross proceeds from this offering are $840,000, before deducting the fees and estimated offering expenses payable by InVivo Therapeutics. The offering closed on November 22, 2019.

H.C. Wainwright & Co. acted as exclusive placement agent for the offering.

A registration statement on Form S-3 (File No. 333-234353) relating to the shares of common stock offered in the offering was filed with the Securities and Exchange Commission, or the SEC, and was declared effective by the SEC on November 14, 2019. The offering was made only by means of a prospectus supplement and accompanying base prospectus, which are part of the effective registration statement. A final prospectus supplement related to the offering was filed with the SEC and is available on the SEC's website at www.sec.gov. Electronic copies of the final prospectus supplement and accompanying base prospectus may also be obtained by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, New York 10022, via e-mail at placements@hcwco.com or via telephone at (646) 975-6996.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp., or the Company, is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children's Hospital and who now is affiliated with Massachusetts General Hospital. The publicly traded company is headquartered in Cambridge, MA.


These press releases may also interest you

at 15:50
Glyscend Inc presented data during the American Diabetes Association 80th Scientific Sessions virtual meeting, June 25-29, 2021, from a study of its proprietary oral polymer duodenal exclusion therapy. The positive data were presented ahead of...

at 15:45
The "Hybrid/Virtual/Decentralized Clinical Trials Market Outlook" report has been added to ResearchAndMarkets.com's offering. Change is hard and it can certainly be intimidating, especially in an area like drug development when there is much at stake...

at 15:31
Members of the media are invited to an important announcement regarding COVID-19 response infrastructure with Jenica Atwin, Member of Parliament for Fredericton, on behalf of the Honourable Catherine McKenna, Minister of Infrastructure and...

at 15:30
The Bio-IT World Conference and Expo will be happening both in-person and online this year?giving our community even more options for learning and connection. Both in-person and virtual attendees will have access to all of the event content: 10...

at 15:21
Please be advised that the Pam Damoff, Parliamentary Secretary to the Minister of Indigenous Services, and Grand Chief Alvin Fiddler, will announce additional support to the Nishnawbe Aski Nation in pursuit of First Nations health transformation....

at 15:19
Principal Technologies Inc. (the "Company") , is pleased to announce that it has closed its previously announced acquisition of an 80% interest (the "Investment") in E&E CRO Consulting GmbH, an arm's length, private company as previously disclosed in...



News published on 22 november 2019 at 16:35 and distributed by: